{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:08:18Z","timestamp":1791216498050,"version":"4.1.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>The neuromuscular adverse events of immune checkpoint inhibitor (ICI) treatment include myositis, polymyalgia rheumatica, myocarditis, and myasthenia syndrome. We report a 47-year old female presenting with external ophthalmoplegia, generalized muscle weakness, and third-degree atrioventricular block 4 weeks after toripalimab treatment for metastatic thymoma. Creatine kinase was elevated to 25,200 U\/l and cardiac troponin I to 2.796 ng\/ml. Autoantibody profiling shows positive anti-ryanodine receptor and anti-acetylcholine receptor antibodies and negative myositis specific antibodies. Repetitive nerve stimulation did not reveal decrement of compound muscle action potentials. Pulse methylprednisolone and immunoglobulin infusion, together with temporary pacemaker insertion normalized her muscle enzyme levels and cardiac rhythm. This is the first report of overlaping neuromuscular adverse event of toripalimab.<\/jats:p>","DOI":"10.3389\/fcvm.2021.714460","type":"journal-article","created":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T03:16:24Z","timestamp":1629083784000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Case Report: The Neuromusclar Triad of Immune Checkpoint Inhibitors: A Case Report of Myositis, Myocarditis, and Myasthenia Gravis Overlap Following Toripalimab Treatment"],"prefix":"10.3389","volume":"8","author":[{"given":"Yue-Bei","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiting","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuming","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s10637-020-00974-7","article-title":"Anti-transcriptional intermediary factor 1-gamma antibody-positive dermatomyositis induced by nivolumab for lung adenocarcinoma: a case report","volume":"39","author":"Osaki","year":"2021","journal-title":"Invest New Drugs."},{"key":"B2","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/CJI.0000000000000196","article-title":"PD-1 inhibitor-associated myopathies: emerging immune-mediated myopathies","volume":"41","author":"Liewluck","year":"2018","journal-title":"J Immunother"},{"key":"B3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1080\/03009742.2019.1596309","article-title":"Nivolumab-induced anti-aminoacyl-tRNA synthetase antibody-positive polymyositis complicated by interstitial pneumonia in a patient with lung adenocarcinoma","volume":"49","author":"Shikano","year":"2020","journal-title":"Scand J Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.nmd.2020.02.013","article-title":"Immune checkpoint inhibitors (ICIs)-related ocular myositis","volume":"30","author":"Garibaldi","year":"2020","journal-title":"Neuromuscul Disord."},{"key":"B5","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ejca.2018.08.021","article-title":"Pembrolizumab-induced dermatomyositis in a patient with metastatic melanoma","volume":"104","author":"Berger","year":"2018","journal-title":"Eur J Cancer."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e1242","DOI":"10.1634\/theoncologist.2019-0911","article-title":"Statin intolerance, anti-HMGCR antibodies, and immune checkpoint inhibitor-associated myositis: a \u201ctwo-hit\u201d autoimmune toxicity or clinical predisposition?","volume":"25","author":"von","year":"2020","journal-title":"Oncologist"},{"key":"B7","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/ajco.13141","article-title":"Immune checkpoint inhibitor use in antisynthetase syndrome","volume":"15","author":"Mackintosh","year":"2019","journal-title":"Asia Pac J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review","volume":"168","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.3390\/ijms21093054","article-title":"Immune checkpoint inhibitor-related myositis: from biology to bedside","volume":"21","author":"Solimando","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/0009-8981(91)90371-i","article-title":"Anti-skeletal muscle and anti-acetylcholine receptor antibodies in patients with thymoma without myasthenia gravis: relation to the onset of myasthenia gravis","volume":"201","author":"Ohta","year":"1991","journal-title":"Clin Chim Acta."},{"key":"B12","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1007\/BF02913506","article-title":"Measurement of antiacetylcholine receptor antibody in patients with thymoma without myasthenia gravis complications","volume":"49","author":"Sakuraba","year":"2001","journal-title":"Jpn J Thorac Cardiovasc Surg"},{"key":"B13","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume-title":"J Immunother Cancer","author":"Safa","year":"2019"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","article-title":"Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan","volume":"89","author":"Suzuki","year":"2017","journal-title":"Neurology."},{"key":"B15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/mus.23882","article-title":"Do acetylcholine receptor and striated muscle antibodies predict the presence of thymoma in patients with myasthenia gravis?","volume":"49","author":"Choi","year":"2014","journal-title":"Muscle Nerve"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1093\/eurheartj\/ehaa051","article-title":"Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis","volume":"41","author":"Zhang","year":"2020","journal-title":"Eur Heart J"},{"key":"B18","first-page":"131","article-title":"Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms","volume-title":"J Clin Invest.","author":"Moslehi","year":"2021"},{"key":"B19","doi-asserted-by":"publisher","first-page":"15567","DOI":"10.1038\/s41598-020-72649-5","article-title":"Landscape of immune checkpoint inhibitor-related adverse events in Chinese population","volume":"10","author":"Li","year":"2020","journal-title":"Sci Rep"},{"key":"B20","doi-asserted-by":"publisher","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","article-title":"NCCN guidelines insights: management of immunotherapy-related toxicities, version 1","volume":"18","author":"Thompson","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"vii29","DOI":"10.1093\/rheumatology\/kez536","article-title":"Management of rheumatic complications of immune checkpoint inhibitor therapy - an oncological perspective","volume":"58","author":"Steven","year":"2019","journal-title":"Rheumatology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1136\/annrheumdis-2020-217139","article-title":"EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors","volume":"80","author":"Kostine","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"7635","DOI":"10.21037\/jtd-2019-thym-12","article-title":"Immunotherapy for thymoma","volume":"12","author":"Jakopovic","year":"2020","journal-title":"J Thorac Dis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s40425-019-0723-9","article-title":"Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma","volume":"7","author":"Rajan","year":"2019","journal-title":"J Immunother Cancer"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.714460\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T03:16:27Z","timestamp":1629083787000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.714460\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,16]]},"references-count":26,"alternative-id":["10.3389\/fcvm.2021.714460"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2021.714460","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,16]]},"article-number":"714460"}}